SCIOTEQ
15.2.2024 12:01:28 CET | Business Wire | Press release
ScioTeq, a leading provider of mission-critical defense and avionics visualization and computing solutions, announces the establishment in Bangalore, India of ScioTeq Pvt Ltd, a wholly owned subsidiary of ScioTeq bv. This move will further extend ScioTeq’s global presence by providing Sales, Procurement and Services at its Bangalore location. Additionally, by joining with local partners it will position ScioTeq to support local trade sales and manufacturing of its products and solutions for the Defense market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215830655/en/
ScioTeq Group Worldwide Locations. (Photo: Business Wire)
This move aligns with the “Make in India” initiative of the Government of India to create and encourage companies to develop, manufacture and assemble products made in India and incentivize dedicated investments into manufacturing. The policy creates a conducive environment for business investment, while building a modern structure and opening new sectors for capital investment. It also creates additional jobs that align with the government’s mantra “Atmanirbhar Bharat” (Self Reliant India) which is focused on promoting indigenization in the Defense sector.
“ScioTeq is excited to evolve our long-term relationship with India’s defense community to the next level with this newly established subsidiary,” said ScioTeq Vice President of Defense & Security, Klaas Peerlinck. “It confirms our commitment as a partner in India’s defense manufacturing establishment as well as providing a base to provide dedicated service and sales needs.”
India’s Defense budget is the fourth largest in the world thus providing various opportunities for Defense industries to engage and partner with them as they develop and upgrade their military capabilities. ScioTeq, the largest independent advanced visualization company globally, has engaged with the Indian defense establishment for over two decades, providing critical visualization solutions. This long-term experience in the country, robust portfolio of visualization and computing displays and now a local base of operations, amply positions ScioTeq for future growth and provides the Indian Defense sector with visualization and computing solutions across all three of its services - the Navy, Army, and Air Force.
“We welcome the move by ScioTeq in incorporating a wholly owned subsidiary in India to drive indigenous manufacturing of their products. We value our association and look forward to working with them,” said Mr. Arun Ramchandani, Head of Larsen & Toubro Defence (L&T). L&T is a multinational Indian conglomerate engaged in various industry sectors including defense.
About ScioTeq
ScioTeq has 35+ years’ experience designing, engineering and manufacturing high-tech, innovative, life- and mission-critical computing & visualization solutions for the Air Traffic Control, Avionics and Defense & Security markets. With headquarters in Belgium and five additional locations worldwide, they are a trusted partner in advanced computing & visualization solutions. ScioTeq products are used in the air, on the ground and at sea, delivering mission-critical information to operators on some of the most advanced platforms on the planet and in some of the most challenging environments.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215830655/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom